IRVINE, CA, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the launch of the Company’s re-designed corporate website. CBIS’ new website is an innovative technology platform that will enable the Company to improve information-sharing with patients, collaborators, stakeholders, and shareholders.
Free Educational Webinars Explore Best Practices In Channel Marketing And Sales — August 20-24, 2018
OWINGS MILLS, MD, Aug. 16, 2018 (GLOBE NEWSWIRE) -- MotorWeek, television’s original and longest-running automotive magazine series, pulls into season 38 with an eye on cultural and lifestyle shifts and their impact on the automotive industry. Host John Davis and the MotorWeek team invite viewers on the ride to experience all that’s new for the 2019 model year, when driver convenience means more than a custom ride and “sharing” extends beyond the road. MotorWeek premieres on public television stations across the country beginning Saturday, September 8 (check local PBS listings).Independence and freedom have always been the cornerstones of car ownership. MotorWeek tracks how unconventional modes and methods of moving people, such as peer-to-peer ride-sharing and rent-by-the-minute electric scooters, are starting to fill those needs but with less owner responsibility. “American car culture has moved far beyond personalizing options on the car itself,” says MotorWeek host John Davis. “It’s about personalizing how people get where they want, and need, to be.”Davis says that dynamic changes are not limited to the car industry – these cultural shifts are affecting lifestyle, budget, environmental footprint and routine. Vehicle usage has become as diverse and personalized as that of our mobile devices. Empowered consumers continue to dictate vehicle assets like reliability, safety, environmental impact, economy and luxury by their purchase preferences, but they are also changing how those vehicles play into their personal lifestyle choices.“Car ownership isn’t going away,” says Davis. “The paradigm for ‘why’ some people are buying personal cars may be shifting, however. Millennials make up the fastest growing segment among vehicle buyers and likely will represent about 40 percent of the U.S. new-vehicle market by 2020*. They are buying at a higher rate than baby boomers and investing more in their vehicle purchase.”“The vehicle focus has traditionally been on driver needs, but with ride-sharing, autonomous and self-driving cars, and services like Uber and Lyft, the backseat has never been more important,” says Davis.Automotive manufacturers are recognizing these trends and offering new subscription vs. traditional lease options that cater to the driver who might want to switch out an SUV for a convertible or sedan, based on their driving needs at the time.With some 17 million new cars purchased last year, car buying clearly remains a priority with consumers. MotorWeek’s reviews and road tests of more than 150 new cars, trucks, and sport utilities each season are a staple of the show, offering viewers a vicarious experience from behind the driver’s seat as well as from behind the wheel. At the start of season 38, MotorWeek will hit the ignition on a broad variety of all-new models including the Jaguar E-Pace, Honda Insight, Chevrolet Silverado, Porsche Boxster GTS, Hyundai Kona, Acura RDX, and the Ferrari 812 Superfast.Season 38 of MotorWeek will also cover the rapid mainstream growth of electrified vehicles, and how to maintain them. MotorWeek’s feature line-up includes the return of popular segments such as Goss’ Garage with master technician Pat Goss offering know-it-yourself car care advice. “Over the Edge” reporter Zach Maskell turns up the fun with a look at the auto world in overdrive, while “FYI” reporter Stephanie Hart has consumer-focused updates on driving style and automotive safety, money-saving advice, as well as the latest technological advances. MotorWeek’s Brian Robinson takes a very hands-on approach for his “Two Wheelin’” reports with reviews of the newest motorcycles and Yolanda Vazquez keeps viewers in the know with consumer news and trends on “Motor News.”MotorWeek airs on 90 percent of PBS stations nationwide. Viewers can find out which public television stations air MotorWeek by going to the station listings page on motorweek.org.Winner of dozens of prestigious automotive journalism awards, MotorWeek is also seen on Discovery’s Velocity cable channel, and on the V-me Spanish-language network.In addition, MotorWeek is available for every type of video screen and mobile device with up-to-the-minute automotive news, instantaneous driving impressions, and exclusive videos online at motorweek.org. In addition, more than 500 of the latest MotorWeek roadtests are available through series partner cars.com.Program excerpts are available at pbs.org/motorweek, and MotorWeek’s YouTube Channel, youtube.com/motorweek, with two million views per month. Viewers can also follow MotorWeek on Facebook, Twitter as well as download complete shows on iTunes.MotorWeek is nationally sponsored by TireRack.com, WeatherTech, HUM by Verizon, RockAuto.com and State Farm. MotorWeek is produced and distributed by Maryland Public Television.
Mondelēz International Delivers Against Its 2020 Impact Goals
Advancements in 2020 environmental sustainability targets developed to reduce CO2 emissions, water usage, waste and packagingAdded healthy lifestyle programs in seven new countries, bringing nutrition education, active play and access to fresh foods to under-served children and their families More than 12 percent of revenue from individually-wrapped portion control snacks that are 200 calories or less; on target to achieve 2020 goal of 15 percentDEERFIELD, Ill., Aug. 21, 2018 (GLOBE NEWSWIRE) -- MondelÄ“z International reported important progress against its 2020 impact goals in its 2017 Impact For Growth Progress Report released today.  The report details progress against sustainable agriculture and environmental footprint goals, as well as global expansion of healthy lifestyle and nutrition programs in at risk communities.  The report also illustrates how the company’s impact programs align with and support the United Nations 2030 Sustainable Development Goals (UN SDGs).“Having a positive impact on our planet and the communities we do business in is core to who we are as a company,” said Dirk Van de Put, Chairman and CEO, Mondelez International. “Today, we’re producing snacks more sustainably, with less energy, water and waste; and sourcing our key ingredients in ways that reduce deforestation in our supply chain.  We’re empowering farmers and investing in community programs that help improve the well-being of children and their families.”MondelÄ“z International’s Impact For Growth platform builds on our legacy of delivering positive impact in four key areas: sustainability, well-being snacks, safety and community. Following are highlights of the company’s 2017 progress:SustainabilityReduced absolute CO2 emissions from manufacturing by 10 percent.Reduced water use by 25 percent at locations where water is most scarce.Eliminated 53,500 metric tonnes of packaging – achieving 80% of our 2020 goal.Increased the impact of Cocoa Life, the company’s sustainable cocoa sourcing program, reaching 120,500 farmers (up 31 percent vs. 2016)  in 1,085 communities (up 26 percent)Promoted environmentally sustainable practices in wheat production across Europe through its Harmony sustainable wheat program, achieving a 20 percent reduction in pesticide useExpanded the company’s Harmony sustainable wheat commitment to now source 100 percent of its wheat need in the EU by 2022Maintained 100 percent RSPO (Roundtable on Sustainable Palm Oil) palm oil goal; with 96 percent of its palm oil traceable back to the millAchieved 15 percent of global eggs sourced were cage-free; on target to use 100 percent cage-free eggs in the U.S. and Canada by 2020 and in the rest of the world by 2025Well-Being SnacksGrew well-being brands at twice the rate of the base portfolioDelivered 12.8 percent of revenue from portion control snacks – individually wrapped and 200 calories or less; and on target to achieve 2020 goal of 15 percentReduced sodium by 1.4 percent across total snack portfolio and 2 percent in Oreo globally; reduced saturated fat in Barni soft cakes by 13 percent and in Ritz and TUC crackers by 2 and 3 percent respectively; and reduced sugar by 1 percent across global belVita and by 5 percent in Green & Black’s chocolatesDoubled the amount of whole grain in Club Social crackers in Latin AmericaSafetyReduced Total Recordable Incidents by 33 percent and Total Incident Rate by 27 percent for all employeesCertified 91 percent of external manufacturers and 98 percent of suppliers against the Foundation for Food Safety Certification 22000, a well-respected Global Food Safety Initiative systemCommunitiesAllocated more than $45 million to healthy lifestyle community partnerships, impacting the lives of 1.5 million children across 18 countries by increasing their nutrition knowledge, providing opportunities for physical activity and access to fresh fruits and vegetables To read an at-a-glance summary, please visit https://bit.ly/2Lcqh9R. For the full report, please visit https://bit.ly/2PmUlD3. And for an infographic detailing progress, please visit https://bit.ly/2vZZJUN.About MondelÄ“z InternationalMondelÄ“z International, Inc. (NASDAQ: MDLZ) is building the best snacking company in the world, with 2017 net revenues of approximately $26 billion. Creating more moments of joy in approximately 160 countries, MondelÄ“z International is a world leader in biscuits, chocolate, gum, candy and powdered beverages, featuring global Power Brands such as Oreo and belVita biscuits; Cadbury Dairy Milk and Milka chocolate; and Trident gum.  MondelÄ“z International is a proud member of the Standard and Poor’s 500, Nasdaq 100 and Dow Jones Sustainability Index. Visit www.mondelezinternational.com or follow the company on Twitter at www.twitter.com/MDLZ.Contact:    Jane Corcoran     +1-847-943-5678     news@mdlz.comA photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/647f4c87-a20e-48b5-b705-969ddd4fe520The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

GURGAON, India and NEW YORK, Aug. 17, 2018 /PRNewswire/ --
TORONTO, Aug. 17, 2018 /CNW/ - VersaPay Corporation (TSXV: VPY) ("VersaPay" or the "Company"), will release its second quarter ended June 30, 2018 on Tuesday, August 28, 2018 after market close. The Company will subsequently hold a conference call on Wednesday, August 29, 2018 at 9:00 AM Eastern Time hosted by Craig O'Neill, Chief Executive Officer, and Shouvik Roy, Chief Financial Officer. A question and answer session will follow the corporate update.
TORONTO, Aug. 17, 2018 /CNW/ - Symbility Solutions Inc. ("Symbility") (TSX.V: SY), a global software company focused on modernizing the insurance industry, confirmed that it will release its second quarter financial results for the three months ended June 30, 2018, before the market opens on Friday, August 24, 2018. The press release, with accompanying financial information, will be posted on Symbility's website at www.symbilitysolutions.com and on www.sedar.com.
Therapix Biosciences logo (PRNewsfoto/Therapix Biosciences)
Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
TEL AVIV, Israel, Aug. 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, issued today its financial summary - second quarter 2018 vs. second quarter 2017 (Note: The functional currency of the Company is New Israeli Shekel; for presentation purposes, the financial data herein is presented in USD): Net loss of $1.2 million, or $0.35 per ADS, for the three months ended June 30, 2018, compared to a net loss of $1.86 million, or $1.10 per ADS, for the three months ended June 30, 2017. For the six months ended June 30, 2018, net loss of $3.26 million, or $0.93 per ADS, compared to a net loss of $2.5 million, or $1.07 per ADS, for the comparable period in 2017. The first half of 2018 net loss included $0.31 million of income due to exchange rate differences on balances of cash and cash equivalents (classified as finance income), versus $0.45 million of expense incurred during the corresponding period in 2017. Research and development ("R&D") expenses amounted to $0.65 million for the three months ended June 30, 2018, compared to approximately $0.46 million for the three months ended June 30, 2017. For the six months ended June 30, 2018, R&D expenses amounted to $1.64 million, compared to $0.7 million for the comparable period in 2017. The increase in R&D expenses for the first half of 2018 resulted primarily from higher expenses in connection with the clinical trials, including expenses for R&D and preclinical studies, wages and related expenses, and regulatory and other expenses. General and administrative expenses ("G&A") amounted to $1 million for the three months ended June 30, 2018, compared to $0.97 million for the three months ended June 30, 2017. For the six months ended June 30, 2018, G&A expenses amounted to $2.14 million, compared to $1.37 million for the comparable period in 2017.  The increase resulted primarily from hiring of new employees, rise in wages and related expenses, investor relations and business expenses, business development expenses as well as professional and directors' fees. These increases were the result of the continuance of the clinical trials and an increase in the number of the Company's employees. Cash totaled $5.1 million as of June 30, 2018, compared to $9.2 million as of December 31, 2017. The decrease in cash primarily resulted from increased R&D and G&A expenses as detailed above. Business update and developments in the Company's clinical R&D programs: Tourette Syndrome (TS): The Phase IIa clinical study for THX-110 in TS at Yale University was completed. Sixteen patients were enrolled in the study. The Company recently reported top line results, and the results were further presented at the annual meeting of the European Society for the Study of Tourette Syndrome by principal investigator Dr. Michael Bloch. The Phase IIb, placebo-controlled 12-week clinical trial for THX-110 in TS will be conducted in Germany. The Company currently anticipates first patient enrollment by the end of the third quarter, as anticipated by the original work plan and timeline. Top line results are expected in the first half of 2020. Obstructive Sleep Apnea (OSA): Within the framework of Therapix's "Entourage Effect" program, the Company has initiated a Phase IIa, sponsor-initiated trial for the treatment of OSA using the Company's proprietary cannabinoid-based technology, THX-110, at Assuta Medical Center in Israel. The study was initiated in June in accordance with the original work plan and timeline. Top line results are expected in the first half of 2019. Chronic Pain: Within the framework of Therapix's "Entourage Effect" program and as previously announced, a Phase IIa investigator-initiated trial was initiated for the treatment of chronic pain using THX-110, in the USA. Mild Cognitive Impairment (MCI): A pre-clinical study evaluating the effect of the THX-130, proprietary ultra-low-dose THC, in a rodent model for cognitive impairment related to traumatic brain injury (TBI) was initiated in Dalhousie University, Halifax, Canada. Results are expected by the second half of this year. Antimicrobial: We are continuing our development program as planned to evaluate the potential efficacy of our proprietary drug candidate THX-150. THX-150 is a pharmaceutical composition of dronabinol (synthetic ∆9-tetrahydracannabinol) with or without palmitoylethanolamide (PEA) along with a selected antibacterial agent that may possess synergy potential. Our objective is to use our entourage technology in association with THC to potentially increase the efficacy of existing antibiotic drugs especially in antibiotic-resistant bacteria strains. In addition, we have initiated a study in an animal model of a microbial infection to test the potential efficacy and safety of THX-150 in accordance with the plan schedule during the second half of 2018. Pain: We have successfully completed two pre-clinical studies in acute and chronic pain in rodent models evaluating the potential efficacy of the Company's proprietary compound THX-160. THX-160 is a pharmaceutical formulation candidate containing a synthetic CB2 receptor agonist. The efficacy of THX-160 was measured as a stand-alone therapy and as an opioid sparing agent. In the preclinical studies, THX-160 was well tolerated and did not cause any significant adverse clinical effects. In addition, efficacy studies demonstrated the analgesic superiority of THX-160 over control and were comparable to high-dose morphine analgesic effects and in some instances exerted greater potency. The efficacy and safety of THX-160 was shown for both acute and chronic pain.     CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Mainly based on an effective exchange rate of 3.65 NIS/USD as of June 30, 2018) June 30, December 31,  2018 2017 2017 Unaudited Audited USD in thousands ASSETS CURRENT ASSETS: Cash  5,103 11,784 9,195 Restricted cash 23 13 24 Accounts receivable 448 242 278 Convertible loan 705 - - 6,279 12,039 9,497 NON-CURRENT ASSETS: Prepaid public offering costs 53 - 19 Property and equipment 53 17 50 106 17 69 6,385 12,056 9,566 LIABILITIES AND EQUITY (DEFICIT) CURRENT LIABILITIES: Trade payables 1,077 543 1,017 Other accounts payable 155 128 160 1,232 671 1,177 EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: Share capital 3,812 3,812 3,812 Share premium 36,989 36,612 36,612    Reserve from share-based payment transactions 5,310 4,584 5,311    Foreign currency translation reserve  432 760 782    Transactions with non-controlling interests 261 261 261 Accumulated deficit (41,651) (34,644) (38,389) Total equity  5,153 11,385 8,389 6,385 12,056 9,566     CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (Based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Six months ended June 30, Three months ended June 30, Year ended December 31, 2018 2017 2018 2017 2017 Unaudited    Audited USD in thousands Research and development expenses, net 1,645 695 650 455 1,943 General and administrative expenses 2,139 1,376 1,000 971 3,810 3,784 2,071 1,650 1,426 5,753 Other expenses - - - - 1 Operating loss 3,784 2,071 1,650 1,426 5,754 Finance income (525) - (437) - (1) Finance expenses 3 428 1 437 491 Loss 3,262 2,499 1,214 1,863 6,244 Attributable to: Equity holders of the Company 3,262 2,499 1,214 1,863 6,244 Non-controlling interests - - - - - 3,262 2,499 1,214 1,863 6,244 Basic and diluted loss per share attributable to equity holders of the Company 0.02 0.03 0.01 0.03 0.05 Basic and diluted loss per ADS attributable to equity holders of the Company 0.93 1.07 0.35 1.10 2.14     CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Six months ended June 30, Three months ended June 30, Year ended December 31, 2018 2017 2018 2017 2017 Unaudited    Audited USD in thousands Net loss 3,262 2,499 1,214 1,863 6,244 Amounts that will not be reclassified  subsequently to profit or loss: Adjustments arising from translation  financial statements from functional  currency to presentation currency 350 (439) 266 (124) (461) Total other comprehensive income (loss) 350 (439) 266 (124) (461) Total comprehensive loss 3,612 2,060 1,480 1,739 5,783 Attributable to:  Equity holders of the Company 3,612 2,060 1,480 1,739 5,783  Non-controlling interests - - - - - 3,612 2,060 1,480 1,739 5,783     CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Mainly based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Attributable to equity holders of the Company  Sharecapital Share premium Reservefrom share-based payment transactions   Foreign currency translation reserve Transactions with non-controlling interests Accumulated deficit Total Unaudited USD in thousands Balance at January 1, 2018 3,812 36,612 5,311 782 261 (38,389) 8,389 Loss - - - - - (3,262) (3,262) Other comprehensive loss - - - (350) - - (350) Total comprehensive loss - - - (350) - (3,262) (3,612) Share-Based payment - - 376 - - - 376 Expiration of share options - 377 (377) - - - - Balance at June 30, 2018 3,812 36,989 5,310 432 261 (41,651) 5,153     CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Mainly based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Attributable to equity holders of the Company Sharecapital Share premium Reservefrom share-based payment transactions Foreign currency translation reserve Transactions with non-controlling interests Accumulated deficit Total Unaudited USD in thousands Balance at January 1, 2017 1,087 26,600 4,449 321 261 (32,145) 573 Loss - - - - - (2,499) (2,499) Other comprehensive income - - - 439 - - 439 Total comprehensive income (loss) - - - 439 - (2,499) (2,060) Share-Based payment - - 135 - - - 135 Issuance of shares (1) 189 769 - - - - 958 Issuance of shares (2) 2,207 7,928 - - - - 10,135 Issuance of shares (3) 329 1,315 - - - - 1,644 Balance at June 30, 2017 3,812 36,612 4,584 760 261 (34,644) 11,385   (1) Net issuance expenses of $61,000   (2) Net issuance expenses of $1,865,000   (3) Net issuance expenses of $156,000     CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Mainly based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Attributable to equity holders of the Company Share capital Sharepremium Reservefrom share-based payment transactions Foreign currency translation reserve Transactions with non-controlling interests Accumulated deficit Total Unaudited USD in thousands Balance at March 31, 2018 3,812 36,829 5,332 698 261 (40,437) 6,495 Loss - - - - - (1,214) (1,214) Other comprehensive loss - - - (266) - - (266) Total comprehensive loss - - - (266) - (1,214) (1,480) Share-based payment - - 138 - - - 138 Expiration of share options - 160 (160) - - - - Balance at June 30, 2018 3,812 36,989 5,310 432 261 (41,651) 5,153     CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Mainly based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Attributable to equity holders of the Company  Sharecapital Share premium Reservefrom share-based payment transactions Foreign currency translation reserve Transactions with non-controlling interests Accumulated deficit Total Unaudited USD in thousands Balance at March 31, 2017 3,483 35,297 4,513 636 261 (32,781) 11,409 Loss - - - - - (1,863) (1,863) Other comprehensive income - - - 124 - - 124 Total comprehensive income (loss) - - - 124 - (1,863) (1,739) Share-based payment - - 71 - - - 71 Issuance of shares (1) 329 1,315 - - - - 1,644 Balance at June 30, 2017 3,812 36,612 4,584 760 261 (34,644) 11,385 (1) Net issuance expenses of $156,000     CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Mainly based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Attributable to equity holders of the Company  Sharecapital Sharepremium Reservefrom share-based payment transactions   Foreign currency translation reserve Transactions with non-controlling interests Accumulated deficit Total Audited USD in thousands Balance at January 1, 2017 1,087 26,600 4,449 321 261 (32,145) 573 Loss - - - - - (6,244) (6,244) Other comprehensive income - - - 461 - - 461 Total comprehensive income (loss) - - - 461 - (6,244) (5,783) Share-Based payment - - 862 - - - 862 Issuance of shares (1) 189 769 - - - - 958 Issuance of shares (2) 2,207 7,928 - - - - 10,135 Issuance of shares (3) 329 1,315 - - - - 1,644 Balance at December 31, 2017 3,812 36,612 5,311 782 261 (38,389) 8,389   (1) Net issuance expenses of $61,000   (2) Net issuance expenses of $1,865,000   (3) Net issuance expenses of $156,000     CONSOLIDATED STATEMENTS OF CASH FLOWS (Based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Six months endedJune 30, Three months endedJune 30, Year ended December 31, 2018 2017 2018 2017 2017 Unaudited    Audited USD in thousands Cash flows from operating activities: Net loss (3,262) (2,499) (1,214) (1,863) (6,244) Adjustments to reconcile net loss to net cash  used in operating activities: Depreciation and amortization 6 2 3 1 5 Gain from sale of equipment - - - - 1 Share-based payment expense 376 135 138 71 862 Finance expenses (incomes), net (512) 446 (422) 453 525 (130) 583 (281) 525 1,393 Working capital adjustments: Increase in accounts receivable (189) (110) (50) (102) (143) Decrease (increase) in trade payables 113 (101) (101) (406) 349 Decrease (increase) in other accounts payable 3 33 (189) (54) 66 (73) (178) (340) (562) 272 Net cash used in operating activities (3,465) (2,094) (1,835) (1,900) (4,579) Cash flows from investing activities: Increase in restricted cash - (2) - (2) (11) Proceed from sale of equipment - - - - 2 Purchase of equipment (12) (7) (3) (7) (44) Grant of convertible loan (500) - (500) - - Net cash used in investing activities (512) (9) (503) (9) (53) Cash flows from financing activities: Prepaid public offering costs (36) - 1 - (18) Proceeds from issuance of share capital (net of issuance expenses) - 13,167 - 1,943 13,193 Net cash provided by (used in) financing activities (36) 13,167 1 1,943 13,175 Exchange rate differences on cash and cash equivalents in foreign currency 308 (446) 218 (453) (527) Translation differences on cash and cash equivalents (387) 490 (287) 149 503 Increase (decrease) in cash (4,092) 11,108 (2,406) (270) 8,519 Cash at the beginning of the period 9,195 676 7,509 12,054 676 Cash at the end of the period 5,103 11,784 5,103 11,784 9,195     R&D AND G&A DETAIL (Based on the average exchange rate of 3.56 NIS/USD for the six-month period ended June 30, 2018) Six months endedJune 30, Three months endedJune 30, Year endedDecember 31, 2018 2017 2018 2017 2017 Unaudited    Audited USD in thousands Research and Development Expenses: Clinical studies 372 256 118 163 511 R&D and preclinical studies 423 158 268 119 362 Wages and related expenses 335 140 127 57 321 Share-based payment 80 24 33 11 103 Regulatory and other expenses 384 117 104 105 276 Chemistry and formulation studies 51 - - - 330 1,645 695 650 455 1,943 General and Administrative Expenses: Investor relations and business expenses 164 388 55 340 871 Professional and director fees 713 394 259 302 1,007 Regulatory expenses 35 53 20 29 80 Business development 484 - 393 - 74 Wages and related expenses 347 343 120 185 808 Office, maintenance, rent and other expenses 100 87 48 55 211 Share-based payment 296 111 105 60 759 2,139 1,376 1,000 971 3,810     Subsequent events:On July 31, 2018, the Company entered into an Agreement for Convertible Equity (the "Convertible Equity Agreement") with Therapix Healthcare Resources, Inc. ("THR"), which is a company incorporated in Delaware and an unaffiliated third party. Under the Convertible Equity Agreement, the Company loaned an aggregate of $1,300,000 (the "Loan") to THR. The maturity date of the Loan, which accrues interest at a rate of nine percent (9%) per annum, will be upon demand of the Company at any time after August 1, 2018, the closing date (the "Maturity Date"). At the election of the Company, the entire Loan shall be converted into that number of shares of the most senior class of shares of THR existing at the time of such conversion, at a price per share equal to the fair market value of such shares as shall be determined by THR's Board of Directors, it being acknowledged that, following the exercise of such conversion right, the Company shall hold 20.96% of THR. In addition, the Company shall have the right to appoint 50% of the members of the THR Board of Directors. The proceeds of the Loan were used by THR to acquire eight pain clinics, seven of which are located in Tennessee and one in Arkansas, as well as a fully equipped laboratory in Tennessee from Anesthesia Services Associates PLLC. (d/b/a Comprehensive Pain Specialist) on August 1, 2018. About Therapix Biosciences Ltd.:Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Please visit our website for more information at www.therapixbio.com. About TXH-110 (Previously referred to as THX-TS01 and THX-OSA01):THX-110 is a combination drug candidate for the treatment of Tourette syndrome, Obstructive Sleep Apnea and pain. It is composed of two components: (1) dronabinol (an FDA approved analog of ∆9-tetrahydracannabinol, or "THC"), and (2) palmitoylethanolamide ("PEA"), which is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules that regulate the expression of genes. The combination of THC and PEA may induce a reaction known as the "Entourage Effect". The basic tenet of the entourage effect is that cannabinoids work together, or possess synergy, and affect the body in a mechanism similar to the body's own endocannabinoid system, which is a group of molecules and receptors in the brain that mediates the psychoactive effects of cannabis. This entourage effect may account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological compounds, PEA may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting their metabolic degradation, and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated that the presence of the PEA molecule could increase the efficacy of THC, while reducing the required dosage and decreasing associated deleterious adverse events. About THX-130:THX-130 is a proprietary, innovative, formulation of ultra-low dose dronabinol, which is intended to provide a treatment for Mild Cognitive Impairment (MCI). Recent pre-clinical animal studies have found that an ultra-low dose of THC could potentially protect the brain from long-term cognitive impairment, which may be caused by aging, lack of oxygen supply, seizures or use of drugs. Certain pre-clinical studies also suggest that ultra-low doses of THC cause animals to improve performance in behavioral tests that measure learning and memory. About THX-150:THX-150 is a drug candidate intended for the treatment of infectious diseases. It consists of dronabinol or dronabinol with PEA and a selected antibacterial agent, which possesses antimicrobial synergy potential. About THX-160:THX-160 is a drug candidate intended for the treatment of pain. It consists of a CB2 receptor agonist with or without the opioid. Forward-Looking Statements:This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the Company's plans with respect to its clinical trials and its intent to report material developments and information regarding such trials. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Therapix Biosciences Ltd.'s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on April 30, 2018 and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. For further information:Oz Adler, CFOOz@therapixbio.com Investor Contact:Investor Relations IR@therapixbio.com   View original content:http://www.prnewswire.com/news-releases/therapix-biosciences-reports-second-quarter-2018-financial-results-and-provides-business-update-300699327.html SOURCE Therapix Biosciences Ltd.
Finance Attitude - 5 incredible investments to supplement Social Security Fund
Majority of Americans have social security trust funds as an integral part of their investment plans. Investors can include other types of investments to supplement social security funds to accumulate wealth.  
Finance Attitude - 8 Common Types of Investment Risks
One of the biggest fears that engulf everybody when they think of investing is the loss of their hard-earned money. A risk is inevitable as every investment involves some degree of risk or taking some calculated risk. It is believed that the higher the risk the higher the returns. A risk is the level of uncertainty that a particular investment will gain if you invest in it or the level of a potential financial loss that you are likely to incur if you invest in a particular asset. Every investor should be concerned about the investment risk as much as they are concerned about the possibility of returns. Investing requires understanding the level of risks involved.  
Finance Attitude - 5 Key Factors to Consider When Choosing an Online Broker
/Lydia Wanjiru/ -- An online broker is quite essential for every investor. It is imperative to carry out a research to determine who an ideal online broker is. Here are a few factors to consider before you choose an online broker: 1.    Minimum Initial Investment Most brokerages set a minimum initial investment or money that has to be deposited into the account to start trading. You can pick the best brokerage in the industry but fail to meet their minimum investment requirement. It is therefore vital for an investor to find out whether the amount of capital they have is sufficient to trade with a particular broker.    
Finance Attitude - 4 Common Types of Alternative Investments
4 Common Types of Alternative Investments
Alternative investments are non -correlated assets that are not among the conventional investments such as stocks, bonds, and cash. It is estimated that since 2005 the global assets have grown twice as fast as the traditional investments according to McKinsey & Company, a global consulting company.  A survey conducted in 2015 showed that advisers had 73% of their clients in alternative investments. The assets increase is caused by the Investors need to diversify their portfolio so as to include a wider range of assets. This helps to reduce volatility, generates better returns, hedges against inflation and to access steady and reliable sources of income. A study conducted by the Informa Investment Solution and published by Blackrock revealed that alternative investments didn’t fall as much as the traditional investment during the 2001-2008 recessions.  Majority of financial advisers recommend investing not more than 25% of your portfolio to alternative investments. This is because a majority of the alternative investments tend to be illiquid. Here is a list of the major alternative investments to include in your portfolio: 1.    Hedge funds Hedge fund is a type of alternative investment where investors pool funds and use different strategies to earn returns. Hedge funds are managed to utilize derivatives and leverage to generate high returns. Hedge funds are classified according to their investment styles and their risks also differ among the different styles. Hedge funds are only accessible to accredited investors and require a large minimum investment but require less SEC regulation than mutual funds and other investment vehicles. Hedge fund requires an investor to keep their money in the fund for at least one year period otherwise known as lock-up period and thus is quite illiquid. 2.    Real estate Real estate is a tangible and immovable property that consists of land and buildings on it and other minerals and water. The benefits of investing in real estate include fairly stable and predictable income (rent), some form of tax benefit (depreciation or the tax deduction for mortgage interest), and some stability. The costs associated with real estate include maintenance, renting, taxes, insurance, and security. Another option of investing in real estate’s is to buy one or more publicly traded REITs where the REIT managers invest your money in various properties that they deem appropriate. REITs pay out 90 percent of the profits they earn every year in the form of a dividend which mostly range or can be more or less than 3.5 % to 5.5%. Another form of real estate investment is Commingled funds which are pools of money made up of contributions from a number of different pension plans or other funds. The commingled fund is managed by a professional money manager which can be a bank, insurance company, or an independent investment counselor. 3.    Cryptocurrencies Alternative Cryptocurrencies otherwise called altcoins are gradually gaining popularity. The first major decentralized cryptocurrency is bitcoin which was introduced in 2009. Bitcoin can be defined as a digital currency, a decentralized network through which bitcoins are transmitted and a chain block or blockchain, which is a decentralized accounting book where all transactions that occur are verified within the network permanently and anonymously. To be able to use bitcoin, the first thing you require is a wallet where you can store your bitcoins and with which you can transfer to other people. Financial advisers recommend not investing anything in bitcoin that you can afford to lose. Investing in bitcoin or any other currency has many risks such as another cryptographic currency could overcome bitcoin, a weakness in the encryption could be discovered, it could be affected if a failure is found in a particular algorithm, the bitcoin client can be updated to use different encryption algorithms, the governments could try to ban or regulate bitcoin and if there is an irreparable flaw could be discovered in the bitcoin protocol. There are other types of altcoins such as litecoin, Etherium, Zcash, Dash, Ripple and Monero. Investors should consider properly allocating Bitcoin, cryptocurrencies and blockchain based technologies as an alternative investment portfolio. In the near future, there will be more and more opportunities to invest in them as these investment opportunities open up. 4.    Commodities Commodities are types of alternative investments and include raw materials that are sold in large quantities and other collectibles examples are oil, wheat, silver, gold, tea, fruits, flowers, fine wine and more. Most commodities are bought and sold with options and futures contracts. Speculators use passive and active investment strategies to invest in commodities. Other types of alternative investments include music royalties, private equity, venture capital, managed futures, derivative contracts, private or direct investments, hard asset lending, distressed debt, liquid alternatives among others.